Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorRiphah International University
About this trial
The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Both males and females
Recurrent depressive disorder (6A71) according to ICD-11,
Asian cut off: Obese and overweight (BMI < 23)
Disqualifiers
Age less than 18
Dementia/ Mentally impaired who can not fill self report performas for inclusion criteria
Patients with comorbid conditions (HTN, CKD) if taking any drug for that condition.
The patient is not an employee of the investigator study site, or a family member of the employees or the investigator, or otherwise dependent on the sponsor, the investigator, or the investigator study site.
Trial design
Treatments tested in this trial
- Metformin
- Antidepressant Therapy
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov